Hyaluronic Acid‐Decorated Liposomes for the Intrapulmonary Delivery of Imatinib: A Targeted Treatment for Postinflammatory Pulmonary Fibrosis

This is the authors' abstract. We don't add key points for this paper.

Nanotechnology allows drugs to be delivered locally and specific cells to be targeted, leading to a promising new therapeutic approach for interstitial lung fibrosis. Hyaluronic acid (HA)-decorated imatinib-loaded liposomes (LIP-HA44700-Im) are developed to target CD44 positive cells for the inhalation treatment of fibrogenic lung disorders. LIP-HA44700-Im are assessed for their uptake and biological activity on respiratory effectors that are related to CD44 expression and compared to undecorated liposomes (LIP). LIP-HA44700-Im uptake is significantly higher than that of LIP, and most of the internalized LIP-HA44700-Im are colocalized with cellular endosomes. LIP-HA44700-Im also reduce lung fibroblasts viability. After 24 h, LIP-HA44700-Im are able to impair collagen 1a1 release and c-Abl phosphorylation. Based on in vitro data, it has been assessed whether the intratracheal administration of LIP-HA44700-Im is able to prevent lung fibrosis in a mouse bleomycin model. The local administration of LIP-HA44700-Im is associated with a significant decrease in alveolar inflammation, lung fibrosis, collagen deposition, and TGF-β expression. LIP-HA44700-Im target and deliver imatinib to lung pathogenic cells in vitro and represent a promising therapeutic option for the local treatment of fibrogenic lung disorders, although further development is required. These in vivo results confirm the validity of targeted nano-based treatment for inflammatory-driven lung fibrogenesis.